• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙库巴曲缬沙坦对一名因长期持续性心房颤动导致心力衰竭且心房利钠肽分泌受损患者的疗效。

Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation.

作者信息

Kurisu Satoshi, Fujiwara Hitoshi

机构信息

Department of Cardiology, National Hospital Organization (NHO) Hiroshimanishi Medical Center, Otake, JPN.

出版信息

Cureus. 2024 Oct 19;16(10):e71844. doi: 10.7759/cureus.71844. eCollection 2024 Oct.

DOI:10.7759/cureus.71844
PMID:39559600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11571103/
Abstract

Atrial natriuretic peptide (ANP) is a circulating hormone released from the atria in response to wall stretch and volume overload in the setting of heart failure. When atrial fibrillation (AF) becomes long-standing persistent, ANP secretion in response to volume overload is impaired due to degenerative changes of the atria. Here, we report a case of heart failure with preserved ejection fraction and impaired ANP secretion due to long-standing AF. N-terminal pro-brain natriuretic peptide (NT-proBNP) level was elevated (269 pg/mL), whereas the increase in ANP level was marginal (46.1 pg/mL), suggesting impaired ANP secretion due to long-standing AF. Valsartan (80 mg/day) was replaced with sacubitril/valsartan (100 mg/day) without changing other medications. Administration of sacubitril/valsartan was effective in improving the patient's symptoms, such as dyspnea and edema, and reducing NT-proBNP level by increasing endogenous ANP level from 46.1 pg/mL to 117 pg/mL in the first four weeks. This case highlights the possibility of impaired ANP secretion in response to volume overload as a predictor of the diuretic effect of sacubitril/valsartan in heart failure. This may lead to individualized treatment for each patient with heart failure based on natriuretic peptide profiles.

摘要

心房利钠肽(ANP)是一种循环激素,在心力衰竭时,心房会因壁张力增加和容量超负荷而释放该激素。当房颤(AF)发展为长期持续性房颤时,由于心房的退行性改变,心房对容量超负荷的反应中ANP分泌受损。在此,我们报告一例射血分数保留的心力衰竭患者,其因长期房颤导致ANP分泌受损。N端前脑利钠肽(NT-proBNP)水平升高(269 pg/mL),而ANP水平仅略有升高(46.1 pg/mL),提示长期房颤导致ANP分泌受损。在未改变其他药物的情况下,将缬沙坦(80 mg/天)换为沙库巴曲缬沙坦(100 mg/天)。给予沙库巴曲缬沙坦可有效改善患者的症状,如呼吸困难和水肿,并在前四周内通过将内源性ANP水平从46.1 pg/mL提高到117 pg/mL来降低NT-proBNP水平。该病例凸显了容量超负荷时ANP分泌受损作为沙库巴曲缬沙坦对心力衰竭利尿作用预测指标的可能性。这可能会根据利钠肽谱为每位心力衰竭患者制定个体化治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/9f522a68d6fe/cureus-0016-00000071844-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/2cf789b939fd/cureus-0016-00000071844-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/988b786419b7/cureus-0016-00000071844-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/dc6a340c17f7/cureus-0016-00000071844-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/a303a5b142c7/cureus-0016-00000071844-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/9f522a68d6fe/cureus-0016-00000071844-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/2cf789b939fd/cureus-0016-00000071844-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/988b786419b7/cureus-0016-00000071844-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/dc6a340c17f7/cureus-0016-00000071844-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/a303a5b142c7/cureus-0016-00000071844-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1777/11571103/9f522a68d6fe/cureus-0016-00000071844-i05.jpg

相似文献

1
Efficacy of Sacubitril/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation.沙库巴曲缬沙坦对一名因长期持续性心房颤动导致心力衰竭且心房利钠肽分泌受损患者的疗效。
Cureus. 2024 Oct 19;16(10):e71844. doi: 10.7759/cureus.71844. eCollection 2024 Oct.
2
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.沙库巴曲缬沙坦对射血分数保留的心力衰竭患者氨基末端 B 型利钠肽前体的影响。
JACC Heart Fail. 2020 May;8(5):372-381. doi: 10.1016/j.jchf.2020.03.002. Epub 2020 Mar 30.
3
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.奈普利酶抑制对各种利钠肽检测的影响。
J Am Coll Cardiol. 2019 Mar 26;73(11):1273-1284. doi: 10.1016/j.jacc.2018.12.063.
4
Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.在射血分数横跨整个范围的心力衰竭患者中,使用沙库巴曲缬沙坦治疗对利钠肽和逆重构的纵向变化。
Int Heart J. 2023 Nov 30;64(6):1071-1078. doi: 10.1536/ihj.23-407. Epub 2023 Nov 14.
5
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.沙库巴曲缬沙坦对慢性心力衰竭脑啡肽酶靶点及利钠肽代谢的影响:一项机制性临床研究。
Eur J Heart Fail. 2019 May;21(5):598-605. doi: 10.1002/ejhf.1342. Epub 2018 Dec 6.
6
Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure.沙库巴曲缬沙坦对心力衰竭代偿期患者利钠肽的影响。
Heart Vessels. 2023 Jun;38(6):773-784. doi: 10.1007/s00380-022-02230-9. Epub 2023 Jan 19.
7
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.利钠肽与沙库巴曲缬沙坦治疗射血分数降低的心力衰竭。
JACC Heart Fail. 2021 Feb;9(2):127-136. doi: 10.1016/j.jchf.2020.09.013. Epub 2020 Nov 11.
8
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.沙库巴曲缬沙坦对比缬沙坦对射血分数保留的心力衰竭前期患者左心房容积的影响:PARABLE 随机临床试验。
JAMA Cardiol. 2023 Apr 1;8(4):366-375. doi: 10.1001/jamacardio.2023.0065.
9
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.沙库巴曲缬沙坦对比标准药物治疗对射血分数保留心力衰竭患者血浆 NT-proBNP 浓度和亚极量运动能力的影响:PARALLAX 随机临床试验。
JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463.
10
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.纳入射血分数降低的心力衰竭住院患者的沙库巴曲缬沙坦治疗的 NT-proBNP 反应:TRANSITION 研究。
JACC Heart Fail. 2020 Oct;8(10):822-833. doi: 10.1016/j.jchf.2020.05.012. Epub 2020 Aug 12.

本文引用的文献

1
Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: A report from the CHART-2 Study.射血分数保留的心力衰竭患者心房颤动进展的临床影响:来自 CHART-2 研究的报告。
Europace. 2024 Aug 30;26(9). doi: 10.1093/europace/euae218.
2
Long-Term Outcomes of Heart Failure With Preserved or Mid-Range Ejection Fraction in the United States.美国射血分数保留或处于中等范围的心力衰竭的长期结局
JACC Adv. 2024 Jul 24;3(7):101027. doi: 10.1016/j.jacadv.2024.101027. eCollection 2024 Jul.
3
Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction.
射血分数保留的心力衰竭中的心肌代谢
J Clin Med. 2024 Feb 20;13(5):1195. doi: 10.3390/jcm13051195.
4
Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis.心房颤动与射血分数降低、轻度降低和保留的心衰不良结局风险:系统评价和荟萃分析。
J Cardiovasc Electrophysiol. 2024 Apr;35(4):715-726. doi: 10.1111/jce.16209. Epub 2024 Feb 13.
5
Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review.心房功能性二尖瓣反流的病理生理学、超声心动图诊断及治疗:美国心脏病学会杂志前沿综述
J Am Coll Cardiol. 2022 Dec 13;80(24):2314-2330. doi: 10.1016/j.jacc.2022.09.046.
6
Atrial functional mitral regurgitation: Insufficiently understood and recognized.心房功能性二尖瓣反流:认识不足,了解不够。
Adv Clin Exp Med. 2022 Nov;31(11):1177-1181. doi: 10.17219/acem/156330.
7
B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?再探B型利钠肽(BNP)——在血管紧张素受体/中性肽链内切酶抑制剂时代,BNP仍是心力衰竭的生物标志物吗?
Biology (Basel). 2022 Jul 9;11(7):1034. doi: 10.3390/biology11071034.
8
Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction.左心房心肌病变与射血分数保留的心力衰竭。
Circ J. 2023 Jul 25;87(8):1039-1046. doi: 10.1253/circj.CJ-21-0795. Epub 2021 Oct 12.
9
Surgical considerations for atrial functional regurgitation of the mitral and tricuspid valves based on the etiological mechanism.基于病因机制的二尖瓣和三尖瓣功能性反流的手术考虑因素。
Gen Thorac Cardiovasc Surg. 2021 Jul;69(7):1041-1049. doi: 10.1007/s11748-021-01629-x. Epub 2021 May 10.
10
Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy.外源性心房利钠肽对射血分数保留的心力衰竭患者的疗效:心房利钠肽缺乏与替代治疗
ESC Heart Fail. 2020 Dec;7(6):4172-4181. doi: 10.1002/ehf2.13042. Epub 2020 Oct 10.